Listen "Treating HCV in PWID: Best Practices"
Episode Synopsis
Take our post-test to claim CME credits. To read a companion newsletter click here.Hepatitis C has become “curable” for >90% of those infected. But while universal HCV elimination is medically possible, this goal is compromised by certain populations who remain underscreened, undertreated, and underserved and continue to spread the virus. One such population is people who inject drugs (PWID). In this issue, Dr. Brianna Norton and Dr. Matthew Akiyama from the Albert Einstein College of Medicine analyze the most important data to explain how substance use impacts adherence and the risk of HCV reinfection. Hosted on Acast. See acast.com/privacy for more information.
More episodes of the podcast eViralHepatitis Review
Medications for CHB
20/10/2022
To Treat or Not To Treat
20/10/2022
HBV & Coinfections
20/10/2022
Hepatitis B: Our Current Understanding
20/10/2022
HBV: Next Steps to a Cure
03/08/2021
HCV: Management Beyond the Liver
04/03/2020
Avoiding “MELD Purgatory”
19/04/2019
Clinical Insight: Engaging PWID in HCV Care
28/12/2018